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Abstract
Background: Compassionate support at the end of life should not be the responsibility of health and social care
professionals alone and requires a response from the wider community. Volunteers, as community members, are a
critical part of many end-of-life care services. The impact of their services on important outcomes such as quality of
life is currently poorly understood. The purpose of this study is to evaluate a series of social action initiatives which
use volunteers to deliver befriending services to people anticipated to be in their last year of life. The aim is to
determine if receiving care from a social action volunteer befriending service plus usual care significantly improves
quality of life in the last year of life.
Methods/design: The research questions will be addressed through a wait-list randomised controlled trial (WLRCT)
and qualitative case study evaluation across 12 sites in England. Participants will be randomly allocated to either
receive the social action volunteer befriending service straight away or receive the intervention after a four week wait
(wait-list arm). The impact of the intervention on end-of-life experience (quality of life as primary outcome, loneliness,
social support) will be measured. Repeated assessments will be carried out at baseline and weeks 4 and 8 for the
intervention arm and weeks 4, 8 and 12 for the wait-list arm. For selected sites case study evaluation will include
interviews, observation and documentary analysis to understand the mechanisms underpinning any found
impact.
Discussion: This study will address the need to both provide services which use social action models to support
end-of-life care in community settings, and to robustly evaluate these models to determine if they influence the
experience of end-of-life care. Such services could work to reduce isolation, help meet emotional needs and maintain
a sense of connectedness to the community. ISRCTN 12929812 Registered 20.5.15
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Background
Providing excellent end-of-life care (defined here as care
in the last year of life) that is responsive to need is critic-
ally important. People want to be cared for as close to
home as possible, especially in the last year of life [1].
However there is poor understanding about which com-
ponents of home based interventions provide the highest
benefit [2, 3]. Understanding the impact of these compo-
nents in context is important so that priority is given to
developing services in a way known to maximise benefit
to people in their last year of life, informal carers and
the services themselves.
With reference to end of life care at home, it is increas-
ingly recognised that compassionate support cannot be
the responsibility of health and social care professionals
alone and requires a response from the wider community.
Volunteers are a critical part of many end-of-life care ser-
vices [4–11] Family members are satisfied with the ser-
vices that volunteers provide at the end-of-life [9], but
there is little evidence of their effect on care outcomes. A
recent systematic review assessing the impact of volun-
teers involved in the direct care of palliative care patients
and their families at the end-of-life only found 8 studies,
none from the UK. They indicate that volunteer involve-
ment has a positive impact on satisfaction with care and
that people may survive longer with home visits from a
volunteer. They conclude that further research is needed
to ensure the resource of volunteers in palliative care is
used appropriately and effectively. Evaluation in well-
designed comparative studies is recommended [12].
In order to meet this knowledge gap, the UK Cabinet
Office funded the provision and evaluation of a range of
social action projects at the end of life. The purpose of
this evaluation is to use a robust and ethical comparative
design to determine the effect of volunteer led social ac-
tion befriending services on quality of life in the last year
of life and how such services can best be implemented
and delivered. Research of this sort can ensure that the
resource of volunteers in palliative care is used appropri-
ately, and in a way which effectively improves quality of
life and the experience in the last year of life. Many vol-
unteer delivered befriending social action services are
being run or developed to provide non-clinical support
to people in their own homes such as companionship,
running errands and providing information. Whilst this
feels intuitively helpful, there is no robust evaluation of
the outcomes of these services nor understanding of
how best to provide such care to maximise effectiveness.
Methods/design
Aims
The primary aim of the study is to evaluate the effective-
ness of receiving care from a social action volunteer
befriending service plus standard care at improving quality
of life as compared to usual care alone for adults in the
last year of life.
The secondary aims are to:
 explore whether the social action volunteer
befriending service reduces loneliness and affects
the perception of social support for adults
 examine whether informal carers for those
receiving care from a social action volunteer
befriending service experience less carer burden
 determine whether receiving care from a social action
volunteer befriending service can affect participant’s
use of other health and social care services
 identify and explore the factors that influence the
impact of social action volunteer befriending
services on end-of-life experience
The intervention
The intervention is based on a model of social action,
and comprises a number of components. Core to the
intervention is that it is provided by a trained volunteer
rather than a paid member of staff, and provides non-
clinical, non-hands on support. Individual support needs
are assessed by the non-clinical volunteer co-ordinator,
and support then provided from a suite of possible op-
tions including ‘befriending’ e.g. sitting with someone to
provide companionship, ‘practical support’ e.g. assisting
with household tasks such as dog walking, gardening,
picking up prescriptions or other errands, and ‘signpost-
ing’ e.g. providing information on other available ser-
vices. Support will be typically provided from 1–3 times
per week, face to face or by telephone, as negotiated be-
tween volunteer providers and participants. Participants
will be in the trial for 8 or 12 weeks (immediate vs wait-list
arm), but their receipt of the social action volunteer ser-
vice can continue outside the trial beyond this point if
needed. Participants are free to withdraw at any time. Par-
ticipants will continue to receive all usual care during this
period. In this study the intervention will be provided
across a number of sites in England who are independently
funded to provide this service by the UK Cabinet Office.
Methods
The study involves two main approaches to data collection.
Wait-list randomised controlled trial
This is a multi-site (n = 12) randomised controlled trial
(RCT) involving a wait-list design. Participants will be
allocated on a 1:1 allocation ratio. A wait-list trial was
chosen as an ethical design which has the strength of an
RCT, but with greater acceptability as all patients eventu-
ally receive the intervention. In a wait-list trial, respon-
dents are either allocated to an intervention group where
they receive the intervention immediately (or as soon after
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randomisation as possible) or to a wait-list group where
they receive the same intervention after a defined period
on a waiting list. While they are on the waiting list pa-
tients receive standard/usual care. Wait-list designs have
been successfully used in end-of-life care research, includ-
ing where there is a pre-existing service [13, 14]. Advan-
tages include having the strength of a RCT in determining
causality, but with greater acceptability as all patients
eventually receive the intervention which can feel more
ethically defensible in end of life care [13–18]. We propose
a short wait period to minimise risk and acknowledge that
interventions need to be effective in a short time period
where life expectancy is short (i.e. a year or less) and attri-
tion due to illness or death highly anticipated [19].
Qualitative case study design
Results generated from the WLRCT will be combined
with a qualitative case study evaluation to understand
the impact of social action befriending services on end-
of-life experience and the factors that can maximize or
minimise that impact. Each site providing the service
comprises a case. The qualitative work stream (case study
evaluation) comprises three distinct research activities
within each chosen case study site:
a. qualitative interviews with i) Patient participants and
informal carers both receiving and having waited to
receive the intervention to explore their experience
of the service (n = 3-6); ii) volunteer staff providing
the intervention to explore their experience of
providing care, motivations, training, and the
research study design etc. (n = 3-6); and iii) staff e.g.
social action volunteers key manager/coordinator,
other responsible stakeholders e.g. chief executive or
general manager, clinical care staff etc. to explore
organizational culture, history of the programme,
selection, training and support of volunteer/ social
action team. Interviews will last approximately an
hour and will be conducted either face to face or
via phone/skype. All participants taking part in the
interviews must be able and willing to give
informed consent.
b. Non participant observation of relevant
organizational meetings, workload allocation,
decision-making activities etc.
c. Documentary data such as service policies, job
descriptions and other relevant written materials
about the services provided as well as contextual
data from the end-of-life care intelligence network
on issues such as place of death etc.
Study setting
Twelve individual sites across England will participate in
this study. Six are run by the same national organisation.
Ten of the sites are hospices, providing end-of-life care
to their populations, one site provides a service jointly
organised between local hospices and a NHS Trust, and
one site is a charity providing care and services to people
with substance abuse issues.
Eligibility for sites to join the study
Sites that will participate in this study have been selected
as part of a government funded initiative to support social
action at the end-of-life in England. A number of organi-
sations tendered to provide these services against a set
specification, and were then shortlisted for interview. Se-
lection considerations at shortlisting and interview in-
cluded the sites’ match to the tender, their capacity to
deliver the proposed service, and their ability and willing-
ness to contribute to the evaluation of these services. All
sites were aware at interview that they would be providing
their services in the context of this study design (Wait-list
trial and case study evaluation).
Study population
Inclusion and exclusion criteria
Patient participant inclusion and exclusion criteria
Outside a trial context, it is anticipated that a wide variety
of people could be referred to such services with a range
of prognosis, diagnosis and backgrounds. We therefore
propose the widest possible inclusion criteria to ensure
that as many people as possible are eligible (to match
likely future service referral criteria).
Inclusion criteria
1. Those eligible to be referred to an end of life care
service determined by the referring organisation/
individual. They should be able to answer ‘no’ to
the ‘surprise question’: ‘Would you be surprised if
the patient dies within a year?’
2. Able to give informed consent.
Exclusion criteria
1. Age <18 years
2. Those who only understand or speak a language in
which our main outcome measure (the WHOQOL-
BREF) is unavailable. This is anticipated to be a
very small number of potential participants as the
WHOQOL-BREF is available in a wide range of
languages, including the main languages spoken in
the participating sites.
3. Those with an anticipated prognosis of < 4 weeks
Family/informal carer
At inclusion, patient participants will be asked to also
identify a family member/informal carer to participate in
the study. Carers, who may or may not be family mem-
bers, will be defined as lay people in a close supportive
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role who share in the illness experience of the patient
[20] or provide emotional support. Patients who are un-
able to identify a family member or informal carer at in-
clusion will not be excluded from the study.
Qualitative case study eligibility criteria
The patient participant inclusion criteria for those invited
to participate in the qualitative component of the study
are the same as for the trial component. Family members/
informal carer and those involved in managing and pro-
viding the intervention (e.g. volunteers, service managers,
health and social care professionals etc.) will be also in-
vited to participate in interviews.
Informal/family carer inclusion criteria for qualitative
case study interviews:
1) Identified as a family/informal carer by the patient
participating in the trial/qualitative case study
2) Over 18 years
3) Able to give informed consent at the time of the
interview
Volunteer/staff inclusion criteria for qualitative case
study interviews:
1) Involved in provision or management of the service
providing the social action befriending service at the
chosen case study site.
Study sample size
Trial study size
Sites funded to provide these services provided an esti-
mate of likely referral numbers to their services. These ag-
gregated numbers indicate that 700 participants are likely
to be referred to the service in the specified trial time
period which indicates a maximum potential study size of
350 patients in the intervention arm and 350 patients in
the wait-list arm of the study recruited from the 12 sites
across England involved in the study. Given that each eli-
gible patient will be asked to nominate a carer, the total
number of carers to be recruited will be up to 700.
Qualitative study size
Three to six (patients, informal carers and volunteers)
and two to three (key managers or co-ordinators) will be
invited to an interview per case study site. Eight sites
will be selected according to their geography and pro-
vider type from the 12 sites involved in the study com-
prising a total sample size of 88–168 participants.
Power calculation and sample size
Trial power calculation and sample size
Three hundred fifty patients per arm are considered to be
sufficient to examine the impact of social action services
(intervention) on quality of life (primary outcome). Trial
power was estimated using a worst case scenario assuming
5 % attrition at primary outcome measure. With 350 or
more participants per arm power will exceed .80 to detect
difference in change over time corresponding to an effect
size of f = .10 (considered a small effect size) between the
intervention and wait-list groups. This power model uses
alpha = .05, two tailed, and uses a conservative correlation
of r = .6 for scores lagged 4 weeks, and r = .5 for 12 weeks.
Case study sample size
A sample size of 8 organisational case studies is consid-
ered to be sufficient to understand the processes and de-
terminants that can potentially maximize or minimise the
impact of social action services (intervention) on end of
life experience. Cases will be sampled from individual
study sites chosen on the basis of their geography in
order to i) maintain a balance between the South and
North of England and ii) maximise heterogeneity on
the basis of the type of the service provider (e.g. hos-
pice, social care or voluntary sector organisation).
Study procedures
The risk of sites experiencing challenges with study pro-
cedures will be minimised by providing study sites with
clear information with what the study involves, provid-
ing access to members of the research team, to answer
queries and address problems experienced by each study
site. Participants’ engagement with the intervention will
be facilitated via a detailed participant information sheet
explaining the nature and the particulars of the study
that will be handed out to all participants prior to com-
mencing the study.
Trial recruitment and informed consent procedure
All those referred to the participating services will be in-
vited to take part in the study. Services will be provided
with information to give to potential referrers so that they
understand the trial component of service delivery, and
the trial eligibility criteria. Appropriately trained staff at
the sites receiving referrals (with Good Clinical Practice
and study specific training on trial and consent proce-
dures) will assess all referrals for eligibility for the study
against trial criteria. Those who are eligible will be given
an invitation letter and participant information sheet and
given time to ask questions and consider trial participa-
tion. Once a referred patient has indicated that they are
happy to participate in the trial, the informed consent
documentation will be explained to them and written
consent taken. These staff are also responsible for
informing Lancaster University of ay adverse events.
Baseline data will then be collected. At this point the
site will contact Lancaster University as part of the
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randomisation procedure, and plan intervention deliv-
ery according to the assigned trial arm.
For trial participants who are receiving their service
within a chosen case study site, a proportion of them
may be invited to participate in a qualitative interview to
discuss their experience of the service. Participants will
give consent for this at initial recruitment and again give
written consent prior to interview.
Randomisation of patients in the trial
Once written informed consent has been obtained to
participate in the trial, and baseline data collected, pa-
tients will be randomly allocated (1:1 allocation ratio) to
either the intervention or the wait-list arm of the trial.
Site coordinators will contact a randomisation line at
Lancaster University, and the next sequence in the allo-
cation (stored in sequentially numbered sealed opaque
envelopes) will be revealed. The randomisation sequence
will be computer generated by an experienced statisti-
cian outside the study context, with rebalance in the
arms after 10 randomisations. Blinding of site staff and
patient participants will not be possible due to the na-
ture of the intervention.
Data collection methods
Outcome measures
The causal impact of the intervention on each aspect of
end of life experience examined in this study will be
measured using a pre-determined set of outcome meas-
urement tools as follows:
 Quality of life (primary outcome measure) is
measured using the World Health Organisation
Quality of Life (WHOQOL-BREF) Scale, a short
validated measure of quality of life and wellbeing,
having wide breadth. Our primary outcome will be
overall quality of life (single response question),
with secondary outcomes the quality of life domains
measured by the WHOQO-BREF (social, environ-
mental, psychological and physical domains) [21].
 Loneliness (secondary outcome measure) is measured
using the De John Greiveld 6-item Loneliness Scale,
a short, well-used, reliable and valid measurement
instrument for overall, emotional, and social loneli-
ness, chosen for brevity and relevance of the items
when mapped onto anticipated outcomes [22].
 Social Support (secondary outcome measure) is
measured using the 8-item modified Medical
Outcomes Study Social Support Survey (mMOS-SS),
a short validated scale covering two domains (emo-
tional and instrumental social support) designed to
identify potentially modifiable social support deficits,
chosen for brevity and relevance of the items when
mapped onto anticipated outcomes [23].
 Carer Burden (secondary outcome measure) is
measured using the Caregiver Burden Scale-End of
Life Care (CBS-EOLC), a reliable and valid measure-
ment tool designed to specifically assess family care-
givers’ burden within the palliative care context,
chosen for brevity and relevance of the items when
mapped onto anticipated outcomes [24].
Socio-demographic data (age, gender, disease diagnosis,
education, marital status, living status, spirituality and eth-
nicity) in the form of a self-completed questionnaire will
be collected from both patients and informal carers at
baseline. At baseline and subsequent time points patient
participants will also be asked to indicate the number, type
and frequency of contact they have with networks of
others (to include social networks and contact with health
and social care service providers). After baseline, week 4,
8 (and 12) questionnaires (with paid return envelope) will
be mailed to participants by research staff at Lancaster
University, with reminders after 2 weeks if required.
Participant timeline
Patient questionnaires
Baseline data (including socio-demographic data such as
age, gender, disease diagnosis, education, marital status,
living status, spirituality and ethnicity) will be collected
from both patients and carers prior to randomisation. The
patients randomised to immediately receive the service
will do so (following any service administrative proce-
dures) and continue to receive it for as long as required as
assessed by the service providers in conjunction with ser-
vice recipients. At week 4 all participants (intervention
arm and wait-list arm) will complete the outcome mea-
sures. At this point, the patients on the wait-list arm will
also commence receiving the service. Measures will be
repeated at week 8. those on the wait-list arm will
complete an additional questionnaire at week 12. Par-
ticipants who withdraw from the service will not be re-
quired to complete questionnaires as this may be due
to deterioration in physical condition, and the risk of
sending questionnaires inappropriately if the services
are unable to provide updates on their health status.
Family members/Informal carers questionnaires
Patients’, family members/ informal carer complete socio-
demographic variables and an outcome measurement tool
for carers (CBS-EOLC). Repeated assessment will be car-
ried out using the same tools (time points).
Additional data
Each participating site will collect information about vol-
unteer visits and record per patient participant details
such as: referral date, consent date, allocation arm, dates
of assessments date allocated to a volunteer, first date of
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volunteer visit, dates/numbers of volunteer visits and
brief indication of support given and dates/numbers of
volunteer support through calls/texts or skype.
A schedule of enrolment, interventions and assess-
ment of outcomes is provided in Table 1.
Data analysis
Descriptive analyses
Exploratory data techniques will be used to examine all
distributions of outcome variables Continuous data will be
summarised using means and standard deviations (SD) if
normally distributed and medians and interquartile ranges
(IOR) if non-normally distributed. Categorical data will be
described using frequencies and percentages.
Comparison between arms
Data will be analysed on an intention to treat basis. A lin-
ear mixed effect model (LME) will be fitted to each out-
come variable at 4, 8 and 12 weeks. The random effects
are intercept and slope; which posit that each participant
has a “personalized” linear response to treatment. The
fixed effects include site, treatment group, and time since
entry, and time interactions, which measure systematic
differences in the rate of change. The assumption of a
common initial mean for all participants is justified by the
randomization of participants into treatment groups. A
major advantage of the LME model is that is does not
require a balanced design; in particular, participant effects
can be estimated using incomplete data. However, missing-
completely-at-random (MCAR) assumption will be tested,
and in case that this assumption is not tenable, multiple
imputation procedures will be employed.
Analyses will be conducted to evaluate potential vari-
ables associated with dropout in wait-list controls, to
prevent that this attrition inflates the apparent treatment
effect at 4 weeks by comparing the intervention group
with only those in the wait-list group with some particular
features. If observed, these confounders will be included
in the LME model to reduce the bias of differential attri-
tion on the estimated treatment effect.
Statistical significance will be assessed at the 5 % (two-
sided) level. All statistical analyses will be conducted
using SPSS v.20.
Missing data
A complete case analysis will be undertaken with a range
of approaches for undertaking sensitivity analyses to ac-
cess the robustness of the findings with respect to miss-
ing data.
Case-study evaluation analyses
Data analyses will follow a framework analysis approach
using a matrix approach informed by the final theory of
change. Framework analysis facilitates within and cross
case pattern matching and has been used in case studies
in palliative and end-of-life care [25, 26]. This analysis
will be integrated with trial data so that an understand-
ing of the factors affecting impact can be compared with
quantitative impact. Cross case pattern matching will
follow to identify thematic factors associated with chal-
lenges and successes in creating impact. This should
provide information on facilitators, challenges, barriers
and strategies for overcoming them.
All qualitative analyses will be performed using NVivo
software.
Handling and storage of data and documents
Access to data
The designated contact person(s) in each study site will
have access to clinical information either contained within
the service referral or available within the organisation if
the potential participant is known to them already. Patient
and carer permission will be required for Lancaster
University to access patient contact details in order to
post subsequent questionnaires to patient and carer
participants. Patient identifiable data will be encrypted
and securely transferred. To ensure confidentiality, data
dispersed to project team members will have any iden-
tifying participant information removed.
Study data (baseline, week 4, 8, 12 questionnaires) will
be returned by post to Lancaster University for entry
onto an SPSS database. Weekly data on volunteer input
will be securely transferred electronically to Lancaster
University for entry onto SPSS. Data will be cleaned and
quality checked independently from the person entering
the data. Range checks will be made for expected data
values. An error rate will be reported.
Confidentiality
Questionnaires will be coded with a unique alpha numeric
identifier which will be kept separately from participant
contact details. No personal identifying information will
be included in the questionnaires. Interviews will be re-
corded only if the patient consents for this to occur. Inter-
views will be digitally recorded on an encrypted recorder
and transferred as soon as possible to a password pro-
tected computer.
Data storage
Data storage and handling will include locked storage,
password protection, encryption and anonymisation of
original data. All audio − recordings will be labelled only
with participants’ alphanumeric codes and stored se-
curely. Direct quotations from respondents will only be
used in such a way as to ensure anonymity.
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Data monitoring
Due to the low risk nature of the intervention, the REC
determined that a data monitoring committee (DMC)
was not required. Regular meetings of protocol authors
and funder representatives will occur where any adverse
or unintended effects of trial interventions or conduct
will be discussed, and stopping decisions made. Site ini-
tiation visits will be made by Lancaster University
Table 1 ELSA: Schedule of enrolment, interventions, and assessments
(X) indicates that week 12 data are only collected for those in the wait arm of the trial (8 weeks after commencement of intervention)
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investigators to explain trial conduct, and an interim




The main risk identified is that participants entered into
the trial who are randomised to the wait-list condition
will potentially receive suboptimal support over that
waiting time, if the intervention is found to be of benefit.
However a number of factors mitigate against this risk:
a) First, there is insufficient current evidence that such
services are of benefit. There are no current trials or
comparative studies of such social action services
which measure outcomes and recent reviews of the
literature about volunteering at the end-of-life argue
strongly for well conducted robust evaluations of
these services.
b) Second, a relatively short wait period has been
chosen to minimise any risks should the service
prove to be of benefit. In the UK people are used to
short waits for services and are unlikely to feel
seriously disadvantaged by a short wait.
c) Third, these social action services are not currently
available to participants, and they would not be
receiving the potential benefit of these services
without the funding available to support this trial.
There is a further risk that these services cause bur-
den, distress or harm rather than the intended benefit.
This is unlikely to be the case, as other similar services
have had reports of satisfaction, and the service provided
is not core clinical work or hands on care but additional
social support. The qualitative interview data collected
from participants should give an indication of experience
which can be used to monitor this possibility. Partici-
pants will also have written information given to them,
and verbally explained, about the complaints and other
procedures to follow if they have any concerns or feed-
back related to either their service provision or the con-
duct of the research. The research team and service
provider sites will work closely together to monitor any
issues and act upon them rapidly.
There is also a risk that patient and carer participants
may be concerned or distressed by some of the ques-
tions asked within the questionnaire toolkit. This risk
will be minimised by using existing well validated stan-
dardised tools, which have been tested in a number of
similar populations, and in different cultures and con-
texts. The tools have been carefully chosen to be short
and easy to complete to minimise participant burden as
much as possible.
Finally, the risk that participants will be contacted to
complete subsequent questionnaires or to be invited to
interview when they may be too unwell through deteri-
oration in their condition, or that carers may be dis-
tressed by such information after a participants’ death
will be mitigated by a clear protocol between the sites
and the University to ensure that this information is se-
curely transferred to avoid such distress.
Potential benefits
Whilst no direct benefit to participants has been prom-
ised, they may enjoy and benefit from the social action
intervention. This intervention can continue after the re-
search phase of the service: services have been asked to
provide this service as per their assessment of need, the
only difference to usual service provision is the wait
period for those allocated to the wait-list condition. In-
directly, our experience of conducting research in pallia-
tive care has shown that patients and informal carers have
been willing to take part in such studies as a method of
reciprocity for the care they have received from palliative
care practitioners and in the knowledge that their par-
ticipation will inform the overall understanding of the
provision of care and benefit others in the future; this
finding is increasingly being supported by a growing
literature [27–29]. In addition, experience with this
kind of research shows that patients and carers often
appreciate the interest shown in their experience and
opinions [30].
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